TRA CỨU
thông tin biểu ghi
  • Sách tham khảo
  • Ký hiệu PL/XG: 616.99 T7107
    Nhan đề: Treatment of tuberculosis :
ISBN 9789241547833
DDC 616.99
Tác giả TT World Health Organization
Nhan đề Treatment of tuberculosis : guidelines / World Health Organization, Stop TB Initiative (World Health Organization)
Lần xuất bản 4th ed.
Thông tin xuất bản Geneva : World Health Organization, 2010
Mô tả vật lý 160 pages. : illustrations ; 24 cm.
Tóm tắt The World Health Organization's Stop TB Department has prepared this fourth edition of Treatment of Tuberculosis: Guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from a second episode of tuberculosis (TB) and conserve patient and programme resources. Second, this fourth edition confirms prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients. Finding and treating multidrug-resistant TB (MDR-TB) in previously treated patients will help to improve the very poor outcomes in these patients. New recommendations for the prompt detection and appropriate treatment of (MDR-TB) cases will also improve access to life-saving care. Third, detecting MDR-TB will require expansion of DST capacity within the context of country-specific, comprehensive plans for laboratory strengthening. This fourth edition provides guidance for treatment approaches in the light of advances in laboratory technology and the country's progress in building laboratory capacity. Fourth, diagnosing MDR-TB cases among previously treated patients and providing effective treatment will greatly help in halting the spread of MDR-TB. This edition also addresses the prevention of acquired MDR-TB, especially among new TB patients who already have isoniazid-resistant Mycobacterium tuberculosis when they start treatment. Finally, this edition strongly reaffirms prior recommendations for supervised treatment, as well as the use of fixed-dose combinations of anti-TB drugs and patient kits as further measures for preventing the acquisition of drug resistance.
Từ khóa tự do Treatment
Từ khóa tự do Antitubercular agents
Từ khóa tự do Thuốc chống lao
Từ khóa tự do Tuberculosis
Từ khóa tự do Bệnh lao
Khoa Khoa Y
Địa chỉ Thư Viện Đại học Nguyễn Tất Thành
000 00000nam#a2200000u##4500
00145675
0022
004EBDA6084-73C6-4776-AC02-92B70B5607C5
005202309261654
008230925s2010 xxu eng
0091 0
020 |a9789241547833
039|a20230926165428|btainguyendientu|c20230926134736|dquyennt|y20230925160000|ztainguyendientu
040 |aNTT
041 |aeng
044 |axxu
082 |a616.99|bT7107|223
110 |aWorld Health Organization
245 |aTreatment of tuberculosis : |bguidelines / |cWorld Health Organization, Stop TB Initiative (World Health Organization)
250 |a4th ed.
260 |aGeneva : |bWorld Health Organization, |c2010
300 |a160 pages. : |billustrations ; |c24 cm.
520 |aThe World Health Organization's Stop TB Department has prepared this fourth edition of Treatment of Tuberculosis: Guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from a second episode of tuberculosis (TB) and conserve patient and programme resources. Second, this fourth edition confirms prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients. Finding and treating multidrug-resistant TB (MDR-TB) in previously treated patients will help to improve the very poor outcomes in these patients. New recommendations for the prompt detection and appropriate treatment of (MDR-TB) cases will also improve access to life-saving care. Third, detecting MDR-TB will require expansion of DST capacity within the context of country-specific, comprehensive plans for laboratory strengthening. This fourth edition provides guidance for treatment approaches in the light of advances in laboratory technology and the country's progress in building laboratory capacity. Fourth, diagnosing MDR-TB cases among previously treated patients and providing effective treatment will greatly help in halting the spread of MDR-TB. This edition also addresses the prevention of acquired MDR-TB, especially among new TB patients who already have isoniazid-resistant Mycobacterium tuberculosis when they start treatment. Finally, this edition strongly reaffirms prior recommendations for supervised treatment, as well as the use of fixed-dose combinations of anti-TB drugs and patient kits as further measures for preventing the acquisition of drug resistance.
653 |aTreatment
653 |aAntitubercular agents
653 |aThuốc chống lao
653 |aTuberculosis
653 |aBệnh lao
690 |aKhoa Y
691 |aY học dự phòng
852 |aThư Viện Đại học Nguyễn Tất Thành
8561|uhttp://elib.ntt.edu.vn/documentdata01/2 tailieuthamkhao/600 congnghe/610 yhoc/anhbiasach/45675_treatmenttuberculosisguidelines_k_001thumbimage.jpg
890|a0|b0|c1|d7
Không tìm thấy biểu ghi nào